Drugs / Busulfan
last change 10 days ago re-read 8 days ago

Busulfan

Small molecule

Developed for
myelodysplastic syndrome · leukemia · plasma cell myeloma · acute myeloid leukemia · lymphoma · disease related to hematopoietic stem cell transplant · acute lymphoblastic leukemia · chronic myeloid leukemia
+170 more · myelodysplastic/myeloproliferative disease · plasma cell neoplasm · neuroblastoma · myeloproliferative neoplasm · Hodgkins lymphoma · childhood acute myeloid leukemia · non-Hodgkin lymphoma · acute myeloid leukemia with 11q23 abnormalities · chronic lymphocytic leukemia/small lymphocytic lymphoma · hematopoietic and lymphoid cell neoplasm · acute myeloid leukemia with t(8;21)(q22;q22) translocation · immunodeficiency disease · myelofibrosis · aplastic anemia · acute myeloid leukemia, t(16;16)(p13.1;q22) · Ewing sarcoma · sickle cell disease · acute leukemia · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · bone marrow failure syndrome · Burkitt lymphoma · central nervous system neoplasm · childhood myelodysplastic syndrome · graft versus host disease · peripheral T-cell lymphoma, not otherwise specified · primary central nervous system lymphoma · acute myeloid leukemia, del(5q31-q32) · anemia · cancer of unknown primary site · childhood malignant neoplasm · chronic granulomatous disease · chronic myelomonocytic leukemia · Diamond-Blackfan anemia · extranodal nasal NK/T cell lymphoma · Fanconi anemia · juvenile myelomonocytic leukemia · lymphoproliferative syndrome · mantle cell lymphoma · myeloid leukemia · sarcoma · severe congenital neutropenia · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myelomonocytic leukemia M4 · adult acute monocytic leukemia · anaplastic large cell lymphoma · Chediak-Higashi syndrome · grade III lymphomatoid granulomatosis · hematologic disorder · hepatosplenic T-cell lymphoma · intraocular lymphoma · large-cell immunoblastic lymphoma · MALT lymphoma · myelodysplastic/myeloproliferative neoplasm · nodal marginal zone B-cell lymphoma · plasma cell leukemia · severe combined immunodeficiency · splenic marginal zone lymphoma · supratentorial primitive neuroectodermal tumor · T-cell non-Hodgkin lymphoma · testicular lymphoma · Waldenstrom macroglobulinemia · Wiskott-Aldrich syndrome · X-linked lymphoproliferative syndrome · acquired polycythemia vera · acute promyelocytic leukemia · adult acute lymphoblastic leukemia · adult T-cell leukemia/lymphoma · angioimmunoblastic T-cell lymphoma · beta thalassemia · beta-thalassemia major · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · breast cancer · cancer · childhood acute lymphoblastic leukemia · childhood acute megakaryoblastic leukemia · congenital amegakaryocytic thrombocytopenia · diffuse large B-cell lymphoma · follicular lymphoma · ganglioneuroblastoma · Griscelli syndrome · kidney cancer · Langerhans cell histiocytosis · leukemia, myeloid, accelerated-phase · lymphoid neoplasm · malignant testicular germ cell tumor · mycosis fungoides and variants · myelodysplastic syndrome associated with isolated del(5q) · myelodysplastic syndrome with excess blasts · myeloid neoplasm · myeloproliferative neoplasm, unclassifiable · paroxysmal nocturnal hemoglobinuria · primary cutaneous B-cell lymphoma · primary myelofibrosis · retinoblastoma · rhabdomyosarcoma · Shwachman-Diamond syndrome · small intestine lymphoma · T-cell immunodeficiency · T-cell large granular lymphocyte leukemia · thalassemia · acute biphenotypic leukemia · acute erythroid leukemia · acute leukemia of ambiguous lineage · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia, FLT3 internal tandem duplication · acute myeloid leukemia, inv(3)(q21.3;q26.2) · acute myeloid leukemia, t(15;17)(q24;q21) · acute myeloid leukemia, t(6;9)(p23;q34.1) · adult central nervous system germ cell tumor · atypical chronic myeloid leukemia, BCR-ABL1 negative · B-cell acute lymphoblastic leukemia · B-cell chronic lymphocytic leukemia · benign neoplasm · central nervous system cancer · central nervous system non-hodgkin lymphoma · childhood brain stem glioma · childhood central nervous system germ cell tumor · childhood cerebellar astrocytic neoplasm · childhood cerebral astrocytoma · childhood ependymoma · childhood germ cell tumor · childhood medulloblastoma · disease of genetic or genomic mechanism · engraftment syndrome · essential thrombocythemia · Ewing sarcoma of bone · extragonadal nonseminomatous germ cell tumor · extraskeletal Ewing sarcoma · hairy cell leukemia · hepatoblastoma · high grade B-cell lymphoma · histiocytosis · immune dysregulation, autoimmunity, and autoinflammation · inborn errors of metabolism · inflammatory breast carcinoma · inherited hemoglobinopathy · kidney neoplasm · lymphoblastic lymphoma · lymphoid hemopathy · lymphoid leukemia · lymphoplasmacytic lymphoma · malignant childhood germ cell neoplasm · marginal zone lymphoma · mature T-cell and NK-cell non-Hodgkin lymphoma · metabolic disease · metastatic malignant neoplasm · mixed phenotype acute leukemia · optic pathway glioma · ovarian mixed germ cell neoplasm · pineoblastoma · post-transplant lymphoproliferative disease · primary cutaneous T-cell non-Hodgkin lymphoma · prolymphocytic leukemia · refractory malignant neoplasm · sickle cell-hemoglobin c disease syndrome · systemic lupus erythematosus · systemic sclerosis · T lymphoblastic leukemia/lymphoma · T-cell and NK-cell neoplasm · testicular germ cell tumor · therapy related acute myeloid leukemia and myelodysplastic syndrome · triple-negative breast carcinoma · urinary bladder cancer · urothelial carcinoma · Wilms tumor · acute undifferentiated leukemia · hemoglobinopathy · T-cell leukemia
Investigated by
National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Fred Hutchinson Cancer Center · Memorial Sloan Kettering Cancer Center · Masonic Cancer Center, University of Minnesota · Peking University People's Hospital
+194 more · City of Hope Medical Center · Seoul National University Hospital · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou First People's Hospital · Institute of Hematology & Blood Diseases Hospital, China · Nanfang Hospital, Southern Medical University · National Heart, Lung, and Blood Institute (NHLBI) · Otsuka Pharmaceutical Development & Commercialization, Inc. · Shanghai Jiao Tong University School of Medicine · University of California, San Francisco · Case Comprehensive Cancer Center · Columbia University · European Organisation for Research and Treatment of Cancer - EORTC · Institut Paoli-Calmettes · Northwestern University · Third Affiliated Hospital, Sun Yat-Sen University · Ann & Robert H Lurie Children's Hospital of Chicago · Celgene Corporation · Children's Oncology Group · First People's Hospital of Chenzhou · H. Lee Moffitt Cancer Center and Research Institute · National Institute of Allergy and Infectious Diseases (NIAID) · National Marrow Donor Program · Roswell Park Cancer Institute · Sichuan University · Zhujiang Hospital · Alliance for Clinical Trials in Oncology · Assistance Publique - Hôpitaux de Paris · Center for International Blood and Marrow Transplant Research · Children's Cancer and Leukaemia Group · Children's Hospital Medical Center, Cincinnati · Genzyme, a Sanofi Company · Inje University · Northside Hospital, Inc. · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · The Seventh Affiliated Hospital of Sun Yat-sen University · University of Chicago · University of Michigan Rogel Cancer Center · Amgen · Asan Medical Center · Association for Training, Education, and Research in Hematology, Immunology, and Transplantation · Barbara Ann Karmanos Cancer Institute · Blood and Marrow Transplant Clinical Trials Network · Blood and Marrow Transplant Group of Georgia · California Institute for Regenerative Medicine (CIRM) · Cancer Research UK · Herbert Irving Comprehensive Cancer Center · Institut Curie · Massachusetts General Hospital · Medical College of Wisconsin · New York Medical College · OHSU Knight Cancer Institute · Otsuka America Pharmaceutical · Otsuka Pharmaceutical Co., Ltd. · Pediatric Brain Tumor Consortium · Samsung Medical Center · Severance Hospital · Societe Francaise Oncologie Pediatrique · Soonchunhyang University Hospital · St. Jude Children's Research Hospital · The First Affiliated Hospital of Soochow University · The Korean Society of Pediatric Hematology Oncology · Ulsan University Hospital · University of Illinois at Chicago · University of Leicester · University of Miami · AIDS Malignancy Consortium · ALL SCTped Forum · ALL-BFM Study Group · Abramson Cancer Center at Penn Medicine · Agence de La Biomédecine · Albert Einstein College of Medicine · Alberta Health services · American Stem Cell, Inc. · all 200 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Busilvex — 2003-07-09 europa.eu ↗
Label expansion US (FDA) BUSULFEX — 2003-01-13 fda.gov ↗
Approved US (FDA) MYLERAN — 1954-06-26 fda.gov ↗

Trials 305 · started per year

today
US approved 1954
EU approved 2003
1
1
1
1
4
3
2
7
9
11
14
7
6
7
9
15
13
17
13
11
13
17
13
12
9
8
13
5
16
6
3
8
8
5
5
5
6
19531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 04 trials
Phase 0 NCT04776850 Dec 2020 → Dec 2022 beta-thalassemia major, sickle cell disease, sickle cell-beta plus-thalassemia, sickle cell-beta zero-thalassemia M.D. Anderson Cancer Center Withdrawn No outcome recorded Stop: Enrollment
Phase 0 NCT03910452 Oct 2019 → Jun 2034 expected chronic granulomatous disease National Institute of Allergy and Infectious Diseases (NIAID) Active not recruiting No outcome recorded
Phase 0 NCT01959477 Mar 2014 → Jan 2015 Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +19 Case Comprehensive Cancer Center Completed No outcome recorded
Phase 0 NCT00426517 Jan 2007 → Nov 2019 immunodeficiency disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 124 trials
Phase 1 NCT06809712 Aug 2022 → Oct 2026 expected hematologic disorder He Huang Recruiting No outcome recorded
Phase 1 NCT04098393 Sep 2019 → Sep 2026 overdue hematopoietic and lymphoid cell neoplasm Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT03517631 Feb 2018 → Dec 2020 AIDS Shanghai Public Health Clinical Center Unknown No outcome recorded
Phase 1 NCT02512497 Dec 2017 → Oct 2023 T-cell large granular lymphocyte leukemia, T-cell prolymphocytic leukemia, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma Ohio State University Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT02500849 Mar 2016 → Jul 2027 expected HIV infectious disease City of Hope Medical Center Active not recruiting No outcome recorded
Phase 1 NCT01961063 Dec 2015 → Jul 2027 expected HIV infectious disease, plasmablastic lymphoma, primary effusion lymphoma City of Hope Medical Center Active not recruiting No outcome recorded
Phase 1 NCT02660281 Oct 2015 → Oct 2019 immunodeficiency disease, myelofibrosis, plasma cell myeloma University of Rochester Completed No outcome recorded
Phase 1 NCT01798004 Apr 2013 → Jul 2015 ganglioneuroblastoma, neuroblastoma Children's Oncology Group Completed No outcome recorded
Phase 1 NCT01969942 Apr 2013 → Oct 2016 Ewing sarcoma University of Louisville Withdrawn No outcome recorded Stop: Enrollment
Phase 1 NCT01471067 Jul 2012 → Apr 2017 disease related to hematopoietic stem cell transplant, leukemia, lymphoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/232 trials
Phase 1/2 NCT06158828 Nov 2024 → Sep 2028 expected acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia Washington University School of Medicine Recruiting No outcome recorded
Phase 1/2 NCT03795597 May 2019 → Nov 2022 plasma cell myeloma Loyola University Unknown No outcome recorded
Phase 1/2 NCT01512888 Aug 2016 → Aug 2026 combined immunodeficiency, X-linked St. Jude Children's Research Hospital Suspended No outcome recorded
Phase 1/2 NCT02589145 Jun 2016 → Apr 2019 lymphoma M.D. Anderson Cancer Center Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT02701673 Jun 2016 → Jun 2019 lymphoma M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1/2 NCT02034630 Jul 2014 → Dec 2023 disease of genetic or genomic mechanism Seoul National University Hospital Unknown No outcome recorded
Phase 1/2 NCT02053545 Dec 2013 → May 2017 leukemia, lymphoma, myelodysplastic syndrome Ann & Robert H Lurie Children's Hospital of Chicago Withdrawn No outcome recorded Stop: Enrollment
Phase 1/2 NCT01983969 Nov 2013 → Nov 2017 cancer of unknown primary site, lymphoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/2 NCT01983761 Nov 2013 → Mar 2014 Hodgkins lymphoma, disease related to transplantation, leukemia, myelodysplastic syndrome +1 Targazyme, Inc. Unknown No outcome recorded
Phase 1/2 NCT02061800 Jun 2013 → Jul 2026 overdue acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia +1 Diane George Active not recruiting No outcome recorded
Phase 2179 trials · 4 met primary
Phase 2 NCT07524530 Oct 2026 → Jun 2033 expected core binding factor acute myeloid leukemia, lymphoma National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT07677306 Jul 2026 → Dec 2027 expected myelodysplastic syndrome Peking University People's Hospital Recruiting No outcome recorded
Phase 2 NCT05565105 Jun 2026 → Jun 2033 expected acute lymphoblastic leukemia, acute myeloid leukemia Guenther Koehne Not yet recruiting No outcome recorded
Phase 2 NCT07085156 Aug 2025 → May 2028 expected myelodysplastic syndrome Ruijin Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06869265 May 2025 → Apr 2028 expected acute myeloid leukemia Peking University People's Hospital Recruiting No outcome recorded
Phase 2 NCT06802315 Feb 2025 → Mar 2030 expected acute myeloid leukemia, leukemia, myeloid, accelerated-phase, myelodysplastic syndrome University of Illinois at Chicago Recruiting No outcome recorded
Phase 2 NCT06769568 Jan 2025 → Sep 2028 expected aplastic anemia, disease related to hematopoietic stem cell transplant Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT06816134 Jan 2025 → Jan 2028 expected acute lymphoblastic leukemia, acute myeloid leukemia The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2 NCT06872333 Nov 2024 → Jun 2030 expected disease related to hematopoietic stem cell transplant, sickle cell disease Masonic Cancer Center, University of Minnesota Recruiting No outcome recorded
Phase 2 NCT05807659 Mar 2023 → Aug 2025 myeloid neoplasm Sichuan University Unknown No outcome recorded
Show all 179 trials opens the full record — a long page
Phase 2/314 trials · 1 met primary
Phase 2/3 NCT07583888 May 2026 → Aug 2027 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2/3 NCT05453552 Jul 2022 → Dec 2023 disease related to hematopoietic stem cell transplant, myelodysplastic syndrome Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT05449899 Jul 2022 → Dec 2023 acute myeloid leukemia, disease related to hematopoietic stem cell transplant Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT04708054 Oct 2021 → Dec 2027 expected acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2/3 NCT04713956 Jan 2021 → Jul 2023 disease related to hematopoietic stem cell transplant, myelodysplastic syndrome Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT03733327 Nov 2018 → Oct 2021 disease related to hematopoietic stem cell transplant, primary central nervous system lymphoma Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT03385096 Jan 2018 → Dec 2020 disease related to hematopoietic stem cell transplant, plasma cell myeloma Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT02671708 Jan 2016 → Feb 2019 acute myeloid leukemia, disease related to hematopoietic stem cell transplant Nanfang Hospital, Southern Medical University Completed No outcome recorded
Phase 2/3 NCT01949129 Apr 2013 → Jun 2030 expected acute lymphoblastic leukemia St. Anna Children's Cancer Research Recruiting No outcome recorded
Phase 2/3 NCT01751997 Jan 2013 → May 2019 acute myeloid leukemia Byung-Sik Cho Completed Met primary
Phase 323 trials · 3 met primary · 4 missed
Phase 3 NCT06613035 Sep 2024 → Sep 2027 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 3 NCT06830421 Aug 2023 → Aug 2029 expected primary central nervous system lymphoma University Hospital Freiburg Recruiting No outcome recorded
Phase 3 NCT05466318 Jul 2022 → Dec 2025 T-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma Sichuan University Unknown No outcome recorded
Phase 3 NCT04221035 Nov 2019 → Nov 2026 expected neuroblastoma Gustave Roussy, Cancer Campus, Grand Paris Recruiting No outcome recorded
Phase 3 NCT03126916 May 2018 → Sep 2030 expected neuroblastoma, nodular ganglioneuroblastoma Children's Oncology Group Recruiting No outcome recorded
Phase 3 NCT02724163 Apr 2016 → Dec 2031 expected acute myeloid leukemia University of Birmingham Active not recruiting No outcome recorded
Phase 3 NCT02670252 Jan 2016 → Feb 2020 acute lymphoblastic leukemia, disease related to hematopoietic stem cell transplant Nanfang Hospital, Southern Medical University Completed Met primary
Phase 3 NCT01471444 Nov 2011 → Dec 2020 disease related to hematopoietic stem cell transplant, leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 3 NCT01413178 Sep 2011 → Mar 2019 plasma cell myeloma M.D. Anderson Cancer Center Completed Met primary
Phase 3 NCT01339910 Jun 2011 → Jan 2017 acute myeloid leukemia Medical College of Wisconsin Terminated Missed primary Stop: Enrollment
Phase 44 trials · 1 missed
Phase 4 NCT06069180 Nov 2023 → Dec 2024 aplastic anemia Peking University People's Hospital Unknown No outcome recorded
Phase 4 NCT01339988 Jun 2011 → Jun 2014 acute leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome Tel-Aviv Sourasky Medical Center Unknown No outcome recorded
Phase 4 NCT01071486 Aug 2009 → Oct 2012 — Rambam Health Care Campus Withdrawn No outcome recorded
Phase 4 NCT00361140 Aug 2005 → Feb 2012 lymphoid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell myeloma H. Lee Moffitt Cancer Center and Research Institute Completed Missed primary
Phase not applicable25 trials
— NCT07644481 Jul 2026 → Dec 2029 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
— NCT07588594 Feb 2026 → May 2028 expected chronic myelomonocytic leukemia Peking University People's Hospital Recruiting No outcome recorded
— NCT06758726 Dec 2024 → Oct 2026 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
— NCT06385808 May 2024 → Dec 2026 expected acute myeloid leukemia First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting No outcome recorded
— NCT03821987 Dec 2018 → Dec 2021 aplastic anemia, engraftment syndrome Peking University People's Hospital Unknown No outcome recorded
— NCT03035422 Jan 2018 → Dec 2021 acute myeloid leukemia Association for Training, Education, and Research in Hematology, Immunology, and Transplantation Completed No outcome recorded
— NCT03079089 Jun 2017 → Sep 2023 lymphoid hemopathy Association for Training, Education, and Research in Hematology, Immunology, and Transplantation Completed No outcome recorded
— NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
— NCT02179359 Sep 2014 → Nov 2024 Diamond-Blackfan anemia, Glanzmann thrombasthenia, Shwachman-Diamond syndrome, paroxysmal nocturnal hemoglobinuria +3 Masonic Cancer Center, University of Minnesota Terminated No outcome recorded
— NCT01795430 Jul 2013 → Mar 2018 Ewing sarcoma of bone, extraskeletal Ewing sarcoma, supratentorial primitive neuroectodermal tumor City of Hope Medical Center Withdrawn No outcome recorded Stop: Enrollment
Comparator or background therapy302 trials
Phase 0 NCT00881556 Background Aug 2009 → Sep 2015 epidermolysis bullosa Columbia University Terminated No outcome recorded
Phase 1 NCT07565220 Background Aug 2026 → Jun 2029 expected acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome Sawa Ito, MD Recruiting No outcome recorded
Phase 1 NCT06996119 Background Jun 2026 → May 2027 expected acute myeloid leukemia, graft versus host disease, myelodysplastic syndrome City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT06506461 Background Mar 2025 → Dec 2029 expected sickle cell disease St. Jude Children's Research Hospital Recruiting No outcome recorded
Phase 1 NCT06900192 Background Mar 2025 → Aug 2029 expected primary progressive multiple sclerosis, secondary progressive multiple sclerosis Stanford University Not yet recruiting No outcome recorded
Show all 302 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2021-08-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Regulatory Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients otsuka.co.jp ↗
Otsuka Pharmaceutical Co., Ltd. today announces it has received regulatory approval in Japan for a once-daily form in pediatric patients of Busulfex Injection 60 mg (generic name is busulfan).
2020-03-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Regulatory Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma otsuka.co.jp ↗
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Busulfex 60 mg for intravenous drip infusion has received regulatory approval in Japan for the additional medical indication as a conditioning regimen prior to autologous hematopoietic stem cell transplantation for patients with malignant lymphoma.
2019-04-17 Mustang Bio, Inc. Results St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine mustangbio.com ↗
Bone marrow harvest, busulfan conditioning and cell infusion were well tolerated.
2018-09-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Regulatory Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults otsuka.co.jp ↗
Otsuka Pharmaceutical Co., Ltd. today announces it has received regulatory approval for a once-daily form of Busulfex Injection 60 mg (generic name is busulfan).

All press releases naming this drug 7 releases

DateIssuerRelease

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 607 sources stand behind the page.

FieldValueCited text
Known as Busulfan “RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4),...” NCT03412266 ↗
599

“Busulfan Plus Cyclophosphamide Vs. Total Body Irradiation Plus Cyclophosphamide for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute T Lymphoblastic...” NCT06673459 ↗

“All patients received alemtuzumab with either fludarabine (150 mg/m(2) )/melphalan (140 mg/m(2) ) (n = 30) or fludarabine/busulfan (n = 1), and unmanipulated marrow grafts from...” PMID 24939325 ↗ Jun 2014

“The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and...” NCT06468267 ↗

“Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4,...” NCT01435447 ↗

“The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem...” NCT01496547 ↗

“Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem...” NCT01049854 ↗

“Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3.” NCT00152113 ↗

“Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases” NCT02483325 ↗

“Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide” NCT02098512 ↗

“pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.” NCT02579967 ↗

Show 589 more sources

Known as 1, 4-Bis[methanesulfonoxy]butane “1, 4-Bis[methanesulfonoxy]butane” NCT01168219 ↗
Known as bulsulfan “conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9.” NCT06625359 ↗
Known as Busilvex “Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases” NCT02483325 ↗
5

“IV Busulfan IV (Busilvex®) - Anti-thymocyte globulines” NCT01572181 ↗

“Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3” NCT01985061 ↗

“Drug: busulfan (Busilvex ®)” NCT01916252 ↗

NCT02349906 ↗

NCT02025881 ↗

Known as busulfan (BSF) “busulfan (BSF)” NCT01707004 ↗
Known as Busulfan (BU) “Busulfan (BU)” NCT01565616 ↗
1

“busulfan (BU)” NCT01707004 ↗

Known as Busulfan (Busulfex), “Busulfan (Busulfex®),” NCT00997386 ↗
Known as busulfex “intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4” NCT00774280 ↗
11

“Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2” NCT01751997 ↗

“intravenous busulfan (busulfex®)” NCT00582933 ↗

“4 doses of IV Busulfex” NCT00531310 ↗

“Busulfan (Busulfex)” NCT06809712 ↗

“Busulfan (Busulfex)” NCT06809699 ↗

“Busulfan (Busulfex)” NCT01176006 ↗

“Busulfan (Busulfex)” NCT01861106 ↗

NCT00582894 ↗

NCT01923935 ↗

NCT00282282 ↗

Show 1 more source

Known as iv-BU “Intravenous Busulfan (iv-Bu) is commonly used as part of preparation regimen for allogeneic hematopoietic stem cell transplantation for patients with acute leukemia.” NCT01498016 ↗
1

“the condition with iv-busulfan (iv-BU) and cyclophosphamide (CTX) is feasible with low toxicity” NCT01435447 ↗

Known as NSC-750 “Iodine-131-labeled Monoclonal Antibody BC8 (anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, ABM; with,...” NCT00002554 ↗
1

“Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, AlBM; with, as indicated, Intrathecal Cytarabine, IT ARA-C, NSC-63878.” NCT00002502 ↗

Known as Spartaject-Busulfan “Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis” NCT00006246 ↗
Known as Tetramethylene bis[methanesulfonate] “Tetramethylene bis[methanesulfonate]” NCT02727803 ↗
Known as ◦Drug: Busulfan “◦Drug: Busulfan” NCT01983761 ↗
Action Deplete “busulfan, a drug that targets myeloid cells, killing them” NCT00092937 ↗
Modality Small molecule “Busulfan and melphalan are both traditional alkylating agents” NCT00427765 ↗
Route Oral “Patients receive oral busulfan every 6 hours” NCT00002547 ↗